- Home
- TURN vs OTLK Comparison
TURN vs OTLK Comparison
Compare TURN & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- OTLK
- Stock Information
- Founded
- TURN 1981
- OTLK 2010
- Country
- TURN United States
- OTLK United States
- Employees
- TURN N/A
- OTLK N/A
- Industry
- TURN Finance/Investors Services
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TURN Finance
- OTLK Health Care
- Exchange
- TURN Nasdaq
- OTLK Nasdaq
- Market Cap
- TURN 46.3M
- OTLK 48.3M
- IPO Year
- TURN N/A
- OTLK 2016
- Fundamental
- Price
- TURN $4.98
- OTLK $0.85
- Analyst Decision
- TURN
- OTLK Buy
- Analyst Count
- TURN 0
- OTLK 5
- Target Price
- TURN N/A
- OTLK $8.50
- AVG Volume (30 Days)
- TURN 22.0K
- OTLK 6.9M
- Earning Date
- TURN 02-26-2018
- OTLK 08-14-2025
- Dividend Yield
- TURN N/A
- OTLK N/A
- EPS Growth
- TURN N/A
- OTLK N/A
- EPS
- TURN 0.30
- OTLK N/A
- Revenue
- TURN $488,011.00
- OTLK $1,505,322.00
- Revenue This Year
- TURN N/A
- OTLK N/A
- Revenue Next Year
- TURN N/A
- OTLK $484.88
- P/E Ratio
- TURN $16.69
- OTLK N/A
- Revenue Growth
- TURN 254.25
- OTLK N/A
- 52 Week Low
- TURN $3.12
- OTLK $0.79
- 52 Week High
- TURN $4.98
- OTLK $8.32
- Technical
- Relative Strength Index (RSI)
- TURN 81.01
- OTLK 29.71
- Support Level
- TURN $4.51
- OTLK $0.79
- Resistance Level
- TURN $4.74
- OTLK $3.39
- Average True Range (ATR)
- TURN 0.12
- OTLK 0.37
- MACD
- TURN 0.04
- OTLK -0.15
- Stochastic Oscillator
- TURN 100.00
- OTLK 2.35
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.